Regeneus Ltd. (CMB) Price & Analysis

Compare

5 Followers

CMB Stock Chart & Stats

AU$0.47

-AU$0.02(-4.44%)

At close: Jan 08 4:00 PM EST

AU$0.47

-AU$0.02(-4.44%)

Day’s Range― - ―

52-Week RangeAU$0.19 - AU$0.60

Previous CloseN/A

Volume21.69K

Average Volume (3M)3.93K

Market Cap

AU$11.25M

Enterprise ValueAU$11.57M

Total Cash (Recent Filing)AU$166.41K

Total Debt (Recent Filing)AU$482.71K

Price to Earnings (P/E)―

Beta-5.28

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding22,968,280

10 Day Avg. Volume7,693

30 Day Avg. Volume3,926

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)2.09

Price to Sales (P/S)5.73

P/FCF Ratio-0.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound & Strong Gross MarginA sharp FY2025 revenue rebound with a ~69% gross margin indicates underlying demand for the company’s candidates and a high-margin product profile. If sustained, this supports scalable unit economics and reduces incremental capital required per revenue dollar as development/commercialization progresses.

Low Financial LeverageModerate debt levels give the company more financial flexibility and lower fixed interest obligations versus highly leveraged peers. This structural balance-sheet strength reduces near-term solvency pressure and preserves optionality for funding clinical programs through equity, grants, or partnerships.

Clinical-stage Regenerative FocusOperating in regenerative medicine positions the company in a structurally growing sector with high unmet medical need and potential for durable IP, partnerships, and milestone-based revenue. Clinical-stage status also creates multiple value inflection points via trial readouts or licensing deals.

Bears Say

High Cash BurnSignificant operating and free cash outflows materially shorten runway absent new funding or rapid revenue scaling. Persistent cash burn forces recurrent capital raises, increases dilution risk, and constrains the ability to sustain or expand clinical programs without external financing over the next several months.

Persistent Losses & Weak Margins Vs CostsDespite revenue growth, large net losses and negative operating margins reflect a cost base far exceeding current revenues. Structurally weak profitability limits internal funding capacity for R&D and commercialization and raises execution risk unless costs are reduced or revenues scale materially.

Declining Equity & Prior Solvency StressA falling equity base and history of negative equity signal prior solvency strain and likely dilution funding events. This weakens the firm's capital buffer, raises the probability of future equity issuance, and can increase financing costs or reduce bargaining power in partnership negotiations.

Regeneus Ltd. News

Cambium Bio Narrows Half-Year Loss and Turns NTAs Positive as Revenue Grows

Regeneus Ltd. ( ($AU:CMB) ) has provided an announcement. Cambium Bio Limited reported a 9% rise in revenue...

16d ago

CMB

Cambium Bio Plans Significant Share Placement to Raise Equity

Regeneus Ltd. ( ($AU:CMB) ) has shared an announcement. Cambium Bio Limited has notified the ASX of its...

25d ago

CMB

Cambium Bio Calls Vote on Share Placement to Boost Major Holder’s Control

Regeneus Ltd. ( ($AU:CMB) ) has provided an announcement. Cambium Bio Limited has called an online general meeting...

25d ago

CMB

Cambium Bio Secures Funding and Advances Toward Phase 3 Trials for Elate Ocular

An update from Regeneus Ltd. ( ($AU:CMB) ) is now available. Cambium Bio has strengthened its funding position...

1M ago

CMB

Cambium Bio Plans Share Placement to Raise Fresh Capital

Regeneus Ltd. ( ($AU:CMB) ) has shared an announcement. Cambium Bio Limited has announced a proposed placement of...

2M ago

CMB

Cambium Bio Raises A$2.4m at Premium from Major Shareholder to Fund Phase 3 Dry Eye Trials

An update from Regeneus Ltd. ( ($AU:CMB) ) is now available. Cambium Bio has secured a A$2.4 million...

2M ago

CMB

Cambium Bio Advances with Strategic Partnerships and R&D Incentives

The latest announcement is out from Regeneus Ltd. ( ($AU:CMB) ). Cambium Bio Limited announced its quarterly cash...

4M ago

CMB

Cambium Bio Corrects Director’s Interest Notice Date

Regeneus Ltd. ( ($AU:CMB) ) has shared an update. Cambium Bio Limited announced a correction to a previously...

4M ago

CMB

Regeneus Ltd. Director Increases Stake with New Share Acquisition

Regeneus Ltd. ( ($AU:CMB) ) has shared an update. Regeneus Ltd. has announced a change in the director’s...

5M ago

CMB

Regeneus Director Increases Stake with New Share Acquisition

Regeneus Ltd. ( ($AU:CMB) ) just unveiled an announcement. Regeneus Ltd. announced a change in the director’s interest,...

5M ago

CMB

CMB FAQ

What was Regeneus Ltd.’s price range in the past 12 months?

Regeneus Ltd. lowest share price was AU$0.19 and its highest was AU$0.60 in the past 12 months.

What is Regeneus Ltd.’s market cap?

Regeneus Ltd.’s market cap is AU$11.25M.

When is Regeneus Ltd.’s upcoming earnings report date?

Regeneus Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 173 days.

How were Regeneus Ltd.’s earnings last quarter?

Regeneus Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.

Is Regeneus Ltd. overvalued?

According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Regeneus Ltd. pay dividends?

Regeneus Ltd. does not currently pay dividends.

What is Regeneus Ltd.’s EPS estimate?

Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Regeneus Ltd. have?

Regeneus Ltd. has 22,968,280 shares outstanding.

What happened to Regeneus Ltd.’s price movement after its last earnings report?

Regeneus Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Regeneus Ltd.?

Currently, no hedge funds are holding shares in AU:CMB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Regeneus Ltd. Stock Smart Score

Outperform

Insider Transactions

Bought Shares

Worth AU$53.3K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

-166.70%

Trailing 12-Months

Asset Growth

-41.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Regeneus Ltd.

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.